Barclays PLC Grows Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Barclays PLC boosted its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 366.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,807 shares of the company’s stock after purchasing an additional 45,402 shares during the quarter. Barclays PLC owned about 0.08% of Phathom Pharmaceuticals worth $1,044,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of PHAT. Jennison Associates LLC raised its position in Phathom Pharmaceuticals by 112.7% in the 3rd quarter. Jennison Associates LLC now owns 5,866,389 shares of the company’s stock valued at $106,064,000 after purchasing an additional 3,108,810 shares during the last quarter. FMR LLC raised its position in Phathom Pharmaceuticals by 49,000.7% during the 3rd quarter. FMR LLC now owns 1,304,114 shares of the company’s stock worth $23,578,000 after buying an additional 1,301,458 shares during the last quarter. Checkpoint Capital L.P. raised its position in Phathom Pharmaceuticals by 71.9% during the 3rd quarter. Checkpoint Capital L.P. now owns 1,504,307 shares of the company’s stock worth $27,198,000 after buying an additional 629,307 shares during the last quarter. Portolan Capital Management LLC raised its position in Phathom Pharmaceuticals by 50.4% during the 3rd quarter. Portolan Capital Management LLC now owns 1,699,918 shares of the company’s stock worth $30,735,000 after buying an additional 569,829 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in Phathom Pharmaceuticals during the 3rd quarter worth $7,952,000. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Insider Activity

In other Phathom Pharmaceuticals news, Director Frank Karbe acquired 12,500 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average cost of $7.93 per share, with a total value of $99,125.00. Following the purchase, the director now owns 57,000 shares in the company, valued at approximately $452,010. The trade was a 28.09 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 24.10% of the company’s stock.

Analysts Set New Price Targets

PHAT has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Wednesday, December 11th. HC Wainwright reiterated a “buy” rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Thursday, December 12th.

Phathom Pharmaceuticals Stock Down 2.2 %

Shares of PHAT opened at $8.00 on Tuesday. The company has a 50-day simple moving average of $11.30 and a 200-day simple moving average of $13.01. The company has a market capitalization of $547.02 million, a PE ratio of -1.41 and a beta of 0.56. Phathom Pharmaceuticals, Inc. has a 52-week low of $6.07 and a 52-week high of $19.71.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.